Stem cells for the treatment of myelin loss

Treatment of myelin loss is particularly suited to therapeutic strategies based on cell replacement. Demyelination represents a defined and functionally debilitating deficit, and remyelination can be accomplished by supplying regions of demyelination with myelinogenic cell populations. Clinical inte...

Full description

Saved in:
Bibliographic Details
Published inTrends in neurosciences (Regular ed.) Vol. 28; no. 12; pp. 677 - 683
Main Author Keirstead, Hans S.
Format Journal Article
LanguageEnglish
Published Oxford Elsevier Ltd 01.12.2005
Elsevier Science
Elsevier Sequoia S.A
Subjects
Adults
Animals
Biochemistry. Physiology. Immunology
Biological and medical sciences
Demyelinating Diseases - physiopathology
Demyelinating Diseases - surgery
Fundamental and applied biological sciences. Psychology
General aspects. Models. Methods
Humans
Injuries
Insecta
Invertebrates
Medical treatment
Myelin Sheath
Nervous system
Neurosciences
Physiology. Development
Stem Cell Transplantation - adverse effects
Stem Cell Transplantation - methods
Stem Cell Transplantation - trends
Stem Cells
Treatment Outcome
Vertebrates: nervous system and sense organs
Ability
Chronic
Myelination
Phenotype
Treatment
Demyelination
Myelin
Stem cell
Central nervous system
Strategy
Transplantation
Review
Online AccessGet full text

Cover

More Information
Summary:Treatment of myelin loss is particularly suited to therapeutic strategies based on cell replacement. Demyelination represents a defined and functionally debilitating deficit, and remyelination can be accomplished by supplying regions of demyelination with myelinogenic cell populations. Clinical interest in stem cells as a source of myelinogenic cells arises from their ability to provide an apparently unlimited cell supply for transplantation, and from recent demonstrations that they can be directed to myelinogenic phenotypes with high purity. Here, I present the emerging perspective that stem-cell-mediated remyelination of the adult CNS is a viable therapeutic strategy, and discuss the challenges to remyelination posed by the environment of acute and chronic injuries.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0166-2236
1878-108X
DOI:10.1016/j.tins.2005.09.008